Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Liver Transpl. 2020 Aug 19;26(11):1430–1440. doi: 10.1002/lt.25837

Table 4:

Outcome Measures per Study Group

Outcome Budesonide Group N=20 Control Group N=20 P
Acute Cellular Rejection 1 (5%) 1 (5%) 1.00
NODATǂ 0 3 (15%) 0.23
Overall infections 0 6 (30%) 0.02
 Bacteremia 0 4 (20%)
 Fungal infection 0 1 (5%)
 Cytomegalovirus infection 0 2 (10%)
ǂ

NODAT, New Onset Diabetes After Transplant